



Safety and Immunogenicity of the COVID-19 Vaccine

Guest Editor:

Dr. Johad F. Khoury

Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA

Deadline for manuscript submissions:

closed (31 March 2024)

Message from the Guest Editor

Dear Colleagues,

COVID-19 vaccines were instant gamechangers when they were introduced in late 2020. Their effect on mortality and severe morbidity and, as a result, on public activities has been tremendous.

On the other hand, some concerns and questions were raised regarding the safety and immunogenicity of these vaccines, both in the general population and in certain risk groups. While data continue to emerge from trials around the world, global policy-making agencies are publishing and updating guidelines and recommendations.

In this Special Issue, we aim to publish the most up-to-date trials regarding the safety of or concerns around COVID-19 vaccines, regardless of the vaccine type or manufacturer, and the immunogenicity that these vaccines provide over time, in the general population as well as in special risk groups.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)